We met with Kelly Dooley (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the new drugs and developing treatment regimens for drug-resistant tuberculosis.
The session entitled: ‘New drugs and new regimens for treating drug-resistant tuberculosis’ was presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
- What are the most important second wave drugs for the treatment of tuberculosis, and what advantages do they offer over older drugs? (0:25)
- Could you tell us a little about the NixTB clinical trial, its findings and their impact on clinical practice? (2:48)
- What biomarkers seem useful in the development of drugs and regimens? (5:39)
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the 31st ECCMID Congress 2021.
Share this Video
Related Videos In Bacterial and Fungal Infections
Esmita Charani: Tackling Global Antimicrobial Resistance
We caught up with touchINFECTIOUS DISEASES expert faculty member, Dr Esmita Charani (Imperial College London, London, UK), to discuss her recent research into the future research priorities to optimise antimicrobial use in humans, and what research gaps still remain. Useful resources: Research roadmap for optimising the use of antibiotics in humans Publication available here: Charani […]
Mahmoud Ghannoum, IDWeek 2021: Phase 3 Oteseconazole Study Findings
It was a pleasure to meet with Prof. Mahmoud Ghannoum (Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA) to a phase 3 study investigating oteseconazole in the treatment of recurrent vulvovaginal candidiasis. The abstract entitled: ‘Susceptibility Testing of Oteseconazole (VT-1161) Against Clinical Isolates from Phase 3 Clinical Studies in Subjects with […]
Mahmoud Ghannoum, IDWeek 2021: Unmet needs in the Treatment Vulvovaginal Candidiasis
It was a pleasure to meet with Prof. Mahmoud Ghannoum (Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA) to discuss the unmet needs in the treatment vulvovaginal candidiasis. The abstract entitled: ‘Susceptibility Testing of Oteseconazole (VT-1161) Against Clinical Isolates from Phase 3 Clinical Studies in Subjects with Recurrent Vulvovaginal Candidiasis’ was […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!